Two different problems, two different treatments

The question is not which injection is better. The question is which problem you actually have — because ChondroFiller and hyaluronic acid (HA) products such as Durolane and Cingal are not rival answers to the same clinical problem. They are designed for different diagnoses entirely.

ChondroFiller is a regenerative collagen scaffold delivered via ultrasound-guided injection into a focal, discrete cartilage defect — a contained lesion, typically Grade III–IV, confirmed on MRI. It works by recruiting the patient's own progenitor cells to promote endogenous repair within that specific cavity. It is not indicated for generalised joint wear.

HA viscosupplements do something quite different: they replenish degraded synovial fluid, restoring lubrication and reducing friction-related pain across a broadly affected joint. They are indicated for mild-to-moderate diffuse osteoarthritis. They do not repair cartilage tissue.

A patient with a focal Grade III–IV lesion is unlikely to benefit from lubrication alone. A patient with diffuse Kellgren-Lawrence Grade II–III osteoarthritis is not a candidate for a focal scaffold. The clinical starting point, for both the patient and the referring clinician, is always diagnosis — not product preference.

What ChondroFiller actually does inside the joint

Delivered as an ultrasound-guided outpatient injection, ChondroFiller Liquid is classified by European regulators as a Class III medical device — the highest tier reserved for implantable devices that interact directly with the body's tissues. The product is a murine-derived native Type I collagen hydrogel, manufactured by Meidrix Biomedicals GmbH, and placed directly into a focal defect of up to 6 cm² under image guidance. Once in position, it self-gels within approximately 3–5 minutes, forming a stable three-dimensional fibrillar matrix that conforms to the contours of the cavity.

The governing mechanism is acellular matrix-induced chondrogenesis. No donor cells are introduced, and no tissue is grown in a laboratory beforehand. Instead, the fibrillar architecture of the scaffold creates a physical and biochemical environment that draws the patient's own progenitor cells — from the surrounding synovium and subchondral bone — into the defect site, where they support the body's own repair processes. The collagen matrix is gradually resorbed as new tissue matures in its place over roughly one to two years, making ChondroFiller neither a permanent filler nor a lubricant.

Structural maturation takes approximately 12 months, and this timeline shapes both rehabilitation and outcome assessment. Published data — largely manufacturer-cited and specialist-reported rather than from independent randomised controlled trials — show IKDC scores improving by approximately 30 points, MOCART cartilage assessment scores in the range of 70–87, and approximately 80% of treated patients reporting good or very good satisfaction. Across appropriately selected cases, some 70–85% are reported to sustain meaningful symptom relief for three to five years from a single treatment course. Independent RCT verification of these figures remains an important evidence gap to acknowledge when interpreting them.

What Durolane and Cingal do — and what they don't

Both Durolane and Cingal are viscosupplements — a category designed around a clear and legitimate goal: replenishing the degraded synovial fluid that normally keeps joint surfaces gliding smoothly. Judged against that goal, they perform well. Neither was engineered to repair cartilage tissue, and it would be unfair to fault them for that absence.

Durolane is a single, 3 mL injection of cross-linked hyaluronic acid. In a 52-week double-blind randomised controlled trial, it produced approximately 62% mean pain reduction at 13 weeks — an effect size of 2.28 — with statistically significant improvements in VAS pain and WOMAC scores sustained through one year. Adverse events were mild and self-limited. The 2022 BMJ systematic review by Pereira et al. (cited 206 times) characterises the broader HA evidence base plainly: viscosupplementation produces a statistically significant but small reduction in OA pain versus placebo. That is an honest summary of where the science stands — clinically useful pain relief, though not dramatic structural change.

Cingal combines cross-linked HA with triamcinolone hexacetonide in one injection. The corticosteroid component acts within 24–48 hours to reduce inflammation and acute pain, while the HA component takes over to sustain joint lubrication for up to approximately 6 months. Three Phase III trials support its superiority over comparator OA injections at 6 months. Corticosteroid in this context addresses an acute-phase role; it is not a long-term management strategy.

The EUROVISCO 2024 consensus guidelines support HA use irrespective of patient age, including those with diabetes and moderate-to-severe obesity, while recommending against injection during an active OA flare or in pregnancy. Guideline bodies are not unanimous — OARSI offers conditional support, whereas AAOS and ACR have taken more sceptical positions — and that clinical debate remains live.

Matching the right treatment to the right diagnosis

The clinical criteria for each treatment are specific enough to function as a decision filter before any injection is discussed.

ChondroFiller is indicated for focal, structurally discrete cartilage lesions — Grade III or IV on standard grading, confirmed on MRI or imaging, and measuring up to 6 cm² in area. The collagen scaffold requires a defined cavity to occupy; in a joint with diffuse osteoarthritis, no such cavity exists, and acellular matrix-induced chondrogenesis has no anatomical target to work within. ChondroFiller is expressly contraindicated in widespread degenerative joint disease.

Hyaluronic acid viscosupplementation addresses the opposite presentation: diffuse, mild-to-moderate OA — typically Kellgren-Lawrence Grade II or III — where the joint surface has worn broadly rather than developing a discrete focal cavity. HA restores lubrication across that degraded surface; it cannot structurally fill or repair a focal lesion. Applying it to a Grade IV focal defect provides temporary friction reduction but leaves the underlying structural void untouched — relief at the wrong level.

A specialist assessment, combining clinical examination with imaging review, is what separates these two diagnostic categories before any treatment pathway is offered. In some advanced presentations — particularly Kellgren-Lawrence Grade III or IV with both focal and diffuse components — a combination approach using ChondroFiller alongside a separate synovial-cushioning agent may be considered. That represents a distinct, separately planned clinical pathway, not an indication to blend the two mechanisms without specialist input.

Durability and evidence — what the data actually shows

The durability gap between these two approaches is real, but the evidence underpinning each figure comes from different sources — and that difference matters.

For ChondroFiller, the 3–5 year durability window derives from manufacturer-cited case data and specialist-reported outcomes rather than independent randomised controlled trials. No published RCT directly compares ChondroFiller to Durolane, Cingal, or any HA product in an equivalent patient population. The absence of such a trial does not nullify the accumulated clinical experience, but it does mean the headline figures await independent verification against a controlled comparator group.

Hyaluronic acid sits on firmer controlled-trial footing within its own indicated population. The Pereira et al. 2022 BMJ systematic review — cited over 200 times — characterises the overall evidence as conclusive for a statistically significant, if modest, reduction in OA pain versus placebo. That evidence base, though, is built on diffuse OA populations; it says nothing about outcomes in the focal-defect presentations where HA would not ordinarily be indicated.

A 2024 PMC narrative review by Brittberg reports improved outcomes from regenerative scaffold approaches compared with HA and physiotherapy for large chondral defects. This provides directional support for the scaffold pathway in that specific clinical context, but it is narrative synthesis rather than a prospective controlled trial — useful framing, not confirmatory data.

Quoting a longer durability figure across unlike patient groups tells a patient very little. Comparing a focal-defect scaffold outcome against a diffuse-OA lubrication outcome conflates populations that were never clinically equivalent. Within each treatment's appropriate diagnostic category, both approaches produce relevant clinical benefit. The gap in head-to-head trial data for ChondroFiller is a genuine limitation — one that independent research will need to address.

Getting the right assessment before choosing

Selecting the appropriate pathway depends on a diagnostic step that neither symptom duration nor online research can substitute for: specialist imaging review to confirm whether the joint shows a focal lesion, diffuse OA, or both. A Grade III–IV discrete defect is a different clinical problem from broadly degraded cartilage, and the treatment approach follows from that distinction — not from the patient's preferred duration of effect or how long other options have been tried.

Useful questions to bring to any specialist assessment include whether imaging confirms a focal lesion or diffuse wear, whether ChondroFiller's specific criteria are met in terms of defect size, grade, and the condition of surrounding cartilage, and what a realistic rehabilitation commitment looks like before function returns.

For UK patients, ChondroFiller is available as a private, ultrasound-guided outpatient injectable treatment — it is not NHS-funded, and it has not received FDA approval in the United States. For those based in London, the London Cartilage Clinic on Harley Street offers imaging-led cartilage assessment and access to ChondroFiller for patients with confirmed focal defects; appointments can be arranged via londoncartilage.com.

1. [1] Single Injection of Cross-Linked Hyaluronate in Knee Osteoarthritis: A 52-Week Double-Blind Randomized Controlled Trial. (2022). https://doi.org/10.3390/pharmaceutics14091783 https://doi.org/10.3390/pharmaceutics14091783
2. [2] First-in-human Study to Evaluate a Single Injection of KiOmedine®CM-Chitosan for Treating Symptomatic Knee Osteoarthritis. (2022). https://doi.org/10.2174/18743129-v16-e2206100 https://doi.org/10.2174/18743129-v16-e2206100
3. [3] Meta Analysis on Outcomes of Intra-Articular Knee Injections: Hyaluronic Acid and Corticosteroid for Knee Osteoarthritis. (2025). https://doi.org/10.61919/c6d0sh59 https://doi.org/10.61919/c6d0sh59
4. [4] EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics. (2024). https://doi.org/10.1177/19476035241271970 https://doi.org/10.1177/19476035241271970